Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mavacamten
Clinical Data
Bristol Myers drug helps patients avoid heart procedures
Bristol Myers is presenting data that shows its targeted heart drug mavacamten helped reduce the risk of needing septal reduction therapy.
Annalee Armstrong
Apr 2, 2022 9:30am
BMS heart drug delayed as risk mitigation program worked out
Nov 19, 2021 8:55am
BMS' $13B MyoKardia heart drug gets along with beta blockers
Nov 13, 2021 8:00am
BMS unveils more mavacamten data, nabbed in $13B MyoKardia deal
May 15, 2021 12:15pm
Bristol Myers strikes $13B MyoKardia buyout to gain heart drug
Oct 5, 2020 8:10am
MyoKardia's mavacamten boosts heart function in phase 3 study
Aug 29, 2020 1:10pm
